登录 / 注册

← 返回资本方

Capital Group

投资主体（类型未细分）

已核出资下限≥$10.03M

投资案例3

机构管理年限—

代表案例

Anthropic开发Claude系列大模型，为个人与企业提供AI助手和API。Legora为法律团队提供AI检索、分析和文档协作工具。Insilico Medicine（英矽智能）以生成式AI设计药物分子并推进临床研发。

搜索

#	公司	市值 / 估值USD	累计融资USD	最后融资 / 上市	主要投资方
01	Anthropic美国开发Claude系列大模型，为个人与企业提供AI助手和API。	$965B私募估值2026-05-28 来源 · 1 Anthropic raises $65B Series H at $965B valuation \ Anthropic ↗2026-10-22	≥$108.45B已核下限	$65BSeries H2026-05-28 来源 · 1 Anthropic raises $65B Series H at $965B valuation \ Anthropic ↗2026-10-22	Altimeter Capital Dragoneer Investment Group Greenoaks Capital Sequoia Capital Capital Group Coatue Management 其余投资方 · 52 D1 Capital GIC ICONIQ Capital XN D.E. Shaw Ventures Founders Fund MGX Fidelity Investments Lightspeed Venture Partners Spark Capital Amazon Baillie Gifford Blackstone General Catalyst Insight Partners Jane Street T. Rowe Price AMP PBC NX1 Temasek Brookfield DST Global NTTVC Micron Samsung SK Hynix BlackRock D1 Goldman Sachs Alternatives Qatar Investment Authority TPG Accel Addition Alpha Wave Appaloosa Bessemer Venture Partners JPMorgan Menlo Ventures Morgan Stanley Investment Management Sands TowerBrook Whale Rock ARK Invest General Atlantic Ontario Teachers WCM Google SK Telecom Salesforce Ventures Sound Ventures Zoom Ventures LG Technology Ventures
26	Legora瑞典/美国为法律团队提供AI检索、分析和文档协作工具。	$8.8B私募估值2026-10-21 来源 · 1 Legora raises $550 million Series E at $8.8 billion valuation to accelerate growth - Legora ↗2026-10-22	≥$1.1B已核下限	$550MSeries E2026-10-21 来源 · 1 Legora raises $550 million Series E at $8.8 billion valuation to accelerate growth - Legora ↗2026-10-22	Atreides Management Baron Capital Capital Group Fidelity Investments Glade Brook J.P. Morgan 其余投资方 · 10 Accel Benchmark Bessemer Venture Partners General Catalyst ICONIQ Capital Insight Partners Menlo Ventures Redpoint Ventures Salesforce Ventures Sands
55	Insilico Medicine（英矽智能）3696.HK · 美国/中国以生成式AI设计药物分子并推进临床研发。	$2.65B上市市值行情日期未提供来源 · 1 Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO ↗2026-10-22	≥$110M已核下限	IPO / 上市2025-12-30	Value Partners PE Fund Eli Lilly Tencent Oaktree Capital Management Schroders（施罗德） Temasek 其余投资方 · 14 UBS China Asset Management（华夏基金） Pacific Asset Management（太平洋资产） CPIC Investment Management HK E Fund Management（易方达基金） Fullgoal Fund Management（富国基金） Harvest Global Investments（嘉实国际） Taikang Life Insurance（泰康人寿） RTW Investments Exome Asset Management Infini Capital Management（无极资本） Capital Group Mirae Asset Securities Co., Ltd. OrbiMed Advisors IV Limited